Literature DB >> 19027857

CAG repeat lengths > or =335 attenuate the phenotype in the R6/2 Huntington's disease transgenic mouse.

I Dragatsis1, D Goldowitz, N Del Mar, Y P Deng, C A Meade, Li Liu, Z Sun, P Dietrich, J Yue, A Reiner.   

Abstract

With spontaneous elongation of the CAG repeat in the R6/2 transgene to > or =335, resulting in a transgene protein too large for passive entry into nuclei via the nuclear pore, we observed an abrupt increase in lifespan to >20 weeks, compared to the 12 weeks common in R6/2 mice with 150 repeats. In the > or =335 CAG mice, large ubiquitinated aggregates of mutant protein were common in neuronal dendrites and perikaryal cytoplasm, but intranuclear aggregates were small and infrequent. Message and protein for the > or =335 CAG transgene were reduced to one-third that in 150 CAG R6/2 mice. Neurological and neurochemical abnormalities were delayed in onset and less severe than in 150 CAG R6/2 mice. These findings suggest that polyQ length and pathogenicity in Huntington's disease may not be linearly related, and pathogenicity may be less severe with extreme repeats. Both diminished mutant protein and reduced nuclear entry may contribute to phenotype attenuation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19027857      PMCID: PMC4461140          DOI: 10.1016/j.nbd.2008.10.009

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  118 in total

1.  NeuN: a useful neuronal marker for diagnostic histopathology.

Authors:  H K Wolf; R Buslei; R Schmidt-Kastner; P K Schmidt-Kastner; T Pietsch; O D Wiestler; I Blümcke
Journal:  J Histochem Cytochem       Date:  1996-10       Impact factor: 2.479

2.  Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates.

Authors:  D Martindale; A Hackam; A Wieczorek; L Ellerby; C Wellington; K McCutcheon; R Singaraja; P Kazemi-Esfarjani; R Devon; S U Kim; D E Bredesen; F Tufaro; M R Hayden
Journal:  Nat Genet       Date:  1998-02       Impact factor: 38.330

3.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain.

Authors:  M DiFiglia; E Sapp; K O Chase; S W Davies; G P Bates; J P Vonsattel; N Aronin
Journal:  Science       Date:  1997-09-26       Impact factor: 47.728

4.  Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation.

Authors:  Aaron B Bowman; Seung-Yun Yoo; Nico P Dantuma; Huda Y Zoghbi
Journal:  Hum Mol Genet       Date:  2005-01-20       Impact factor: 6.150

5.  Decreased expression of striatal signaling genes in a mouse model of Huntington's disease.

Authors:  R Luthi-Carter; A Strand; N L Peters; S M Solano; Z R Hollingsworth; A S Menon; A S Frey; B S Spektor; E B Penney; G Schilling; C A Ross; D R Borchelt; S J Tapscott; A B Young; J H Cha; J M Olson
Journal:  Hum Mol Genet       Date:  2000-05-22       Impact factor: 6.150

6.  Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation.

Authors:  Richard R Ribchester; Derek Thomson; Nigel I Wood; Tim Hinks; Thomas H Gillingwater; Thomas M Wishart; Felipe A Court; A Jennifer Morton
Journal:  Eur J Neurosci       Date:  2004-12       Impact factor: 3.386

7.  Relationship between trinucleotide repeats and neuropathological changes in Huntington's disease.

Authors:  S Furtado; O Suchowersky; B Rewcastle; L Graham; M L Klimek; A Garber
Journal:  Ann Neurol       Date:  1996-01       Impact factor: 10.422

8.  R6/2 neurons with intranuclear inclusions survive for prolonged periods in the brains of chimeric mice.

Authors:  Anton Reiner; Nobel Del Mar; Yun-Ping Deng; Christopher A Meade; Zhiqiang Sun; Daniel Goldowitz
Journal:  J Comp Neurol       Date:  2007-12-20       Impact factor: 3.215

9.  Nucleocytoplasmic transport signals affect the age at onset of abnormalities in knock-in mice expressing polyglutamine within an ectopic protein context.

Authors:  Walker S Jackson; Sara J Tallaksen-Greene; Roger L Albin; Peter J Detloff
Journal:  Hum Mol Genet       Date:  2003-07-01       Impact factor: 6.150

10.  Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells.

Authors:  Wen Yang; John R Dunlap; Richard B Andrews; Ronald Wetzel
Journal:  Hum Mol Genet       Date:  2002-11-01       Impact factor: 6.150

View more
  38 in total

1.  A critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington's disease.

Authors:  Damian M Cummings; Yasaman Alaghband; Miriam A Hickey; Prasad R Joshi; S Candice Hong; Chunni Zhu; Timothy K Ando; Véronique M André; Carlos Cepeda; Joseph B Watson; Michael S Levine
Journal:  J Neurophysiol       Date:  2011-11-09       Impact factor: 2.714

2.  Early autophagic response in a novel knock-in model of Huntington disease.

Authors:  Mary Y Heng; Duy K Duong; Roger L Albin; Sara J Tallaksen-Greene; Jesse M Hunter; Mathieu J Lesort; Alex Osmand; Henry L Paulson; Peter J Detloff
Journal:  Hum Mol Genet       Date:  2010-07-08       Impact factor: 6.150

Review 3.  Aggregation formation in the polyglutamine diseases: protection at a cost?

Authors:  Tiffany W Todd; Janghoo Lim
Journal:  Mol Cells       Date:  2013-06-19       Impact factor: 5.034

4.  BDNF may play a differential role in the protective effect of the mGluR2/3 agonist LY379268 on striatal projection neurons in R6/2 Huntington's disease mice.

Authors:  A Reiner; H B Wang; N Del Mar; K Sakata; W Yoo; Y P Deng
Journal:  Brain Res       Date:  2012-07-20       Impact factor: 3.252

5.  Translation of HTT mRNA with expanded CAG repeats is regulated by the MID1-PP2A protein complex.

Authors:  Sybille Krauss; Nadine Griesche; Ewa Jastrzebska; Changwei Chen; Désiree Rutschow; Clemens Achmüller; Stephanie Dorn; Sylvia M Boesch; Maciej Lalowski; Erich Wanker; Rainer Schneider; Susann Schweiger
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

6.  The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease mice.

Authors:  A Reiner; D C Lafferty; H B Wang; N Del Mar; Y P Deng
Journal:  Neurobiol Dis       Date:  2012-03-27       Impact factor: 5.996

7.  Allelic series of Huntington's disease knock-in mice reveals expression discorrelates.

Authors:  Ashish Kumar; Jennifer Zhang; Sara Tallaksen-Greene; Michael R Crowley; David K Crossman; A Jennifer Morton; Thomas Van Groen; Inga Kadish; Roger L Albin; Mathieu Lesort; Peter J Detloff
Journal:  Hum Mol Genet       Date:  2016-02-14       Impact factor: 6.150

8.  Force-plate quantification of progressive behavioral deficits in the R6/2 mouse model of Huntington's disease.

Authors:  Stephen C Fowler; Benjamin R Miller; Thomas W Gaither; Michael A Johnson; George V Rebec
Journal:  Behav Brain Res       Date:  2009-03-28       Impact factor: 3.332

9.  Comprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline.

Authors:  Liliana B Menalled; Monica Patry; Natalie Ragland; Phillip A S Lowden; Jennifer Goodman; Jennie Minnich; Benjamin Zahasky; Larry Park; Janet Leeds; David Howland; Ethan Signer; Allan J Tobin; Daniela Brunner
Journal:  PLoS One       Date:  2010-03-22       Impact factor: 3.240

10.  Rescuing the Corticostriatal Synaptic Disconnection in the R6/2 Mouse Model of Huntington's Disease: Exercise, Adenosine Receptors and Ampakines.

Authors:  Carlos Cepeda; Damian M Cummings; Miriam A Hickey; Max Kleiman-Weiner; Jane Y Chen; Joseph B Watson; Michael S Levine
Journal:  PLoS Curr       Date:  2010-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.